phenindione and dabigatran

phenindione has been researched along with dabigatran in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bertrand, M; Blotière, PO; Bouillon, K; Maura, G; Ricordeau, P; Zureik, M1
Bonello, L; Camoin-Jau, L; Gaubert, M; Laine, M; Paganelli, F; Resseguier, N1

Other Studies

2 other study(ies) available for phenindione and dabigatran

ArticleYear
Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study.
    The Lancet. Haematology, 2015, Volume: 2, Issue:4

    Topics: Acenocoumarol; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Phenindione; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thromboembolism; Vitamin K; Warfarin

2015
Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation.
    Journal of thrombosis and haemostasis : JTH, 2018, Volume: 16, Issue:3

    Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Angiography; Dabigatran; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Incidence; Ischemia; Kaplan-Meier Estimate; Male; Middle Aged; Outcome Assessment, Health Care; Patient Safety; Phenindione; Propensity Score; Proportional Hazards Models; Risk; Treatment Outcome; Vitamin K

2018